P7.2: IDENTIFICATION OF VASCULAR AND CIRCULATING BIOMARKERS TO PREDICT OUTCOME IN PATIENTS AFFECTED BY SEPTIC SHOCK


To link to this article: https://doi.org/10.1016/j.artres.2014.09.164

Published online: 7 December 2019
The RI value was significantly reduced by beetroot ingestion (pre-beetroot RI = 0.75 ± 0.03 versus post-beetroot RI = 0.72±0.05; pre-water RI = 0.75±0.06 versus post-water RI = 0.76±0.05; P = 0.02).

Conclusion: Our preliminary findings suggest that the supplementation of pharmacologic therapy with dietary nitrate through beetroot juice could prevent cardiovascular events and progression of renal disease in CKD patients.

P6.10 PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION. A COCHRANE REVIEW.

T. De Backer 1,2, V. Kamoen 2, R. Vander Stichele 2,3, L. Campens 3,4, D. De Bacquer 2, L. Van Bortel 1
1Heymans Institute of Pharmacology, Ghent, Belgium 2Cardiovascular Center, Gent, Belgium 3Dept of Epidemiology and Public Health, Gent, Belgium

Intermittent claudication (IC) is a symptomatic form of peripheral arterial disease (PAD) (pain in the lower limbs with walking and relieved by rest). Propionyl-L-carnitine (PLC) is a drug which may lower the symptoms of PAD.

Is PLC efficacious in improving clinical outcomes in IC patients? For this Cochrane review randomized controlled trials in patients with IC receiving PLC compared with placebo or other intervention were selected. Pain-free and maximal walking performance were analyzed by standardized exercise test. ABI, quality of life and adverse events were assessed. 13 Studies were included in this review (1423 patients). The results of these selected trials were brought together in patient pools. For the maximal walking distance, the mean difference in walking performance after use of PLC compared to placebo was an absolute increase of 50.86 m (95% CI 50.34 to 51.38) or a 26% relative improvement (23 to 28%). For the pain-free walking distance, the improvement in walking performance with PLC compared to placebo was an absolute increase of 32.98 m (32.60 to 33.37) or a 31% relative improvement (28 to 34%). PLC had an 0.09 (0.08 to 0.09) improvement in ABI over placebo. The adverse events of PLC were similar as in the control group and PLC seemed well tolerated and safe. PLC 1-2g a day costs 0.30 to 0.70 €.

PLC for IC shows a significant, though mild to moderate improvement of walking distances and ABI compared to placebo. The safety of PLC is comparable to placebo. In practice, PLC could be useful adjuvant to classic IC-therapies or when these are contra-indicated, not feasible or ineffective. This work is a Cochrane review. The data presented here presented are provisional (as the review has not yet been published).


P6.11 PHOSPHODIESTERASE TYPE-5 INHIBITOR USE IN TYPE 2 DIABETES IS ASSOCIATED WITH A REDUCTION IN ALL CAUSE MORTALITY

S. Anderson 1,2, D. Hutchings 1,2, C. Kwok 1,2, A. Trafford 1,2, A. Heald 1,2,3
1University of Manchester, Manchester, UK 2Leighton Hospital, Crewe, UK

Background: Phosphodiesterase type-5 inhibitors (PDE5Is) exert cardioprotective effects in small mammal models of myocardial ischemia. There is currently little data on whether a similar effect exists in humans. We determined whether PDE5I use in males with type 2 diabetes (T2DM) was associated with reduced mortality.

Methods: We retrospectively analysed the pseudoanonymised records of 48 GP practices in Cheshire, UK and identified all 7029 men (mean age 72.8 years) diagnosed with T2DM before 1 January 2007. Baseline clinical characteristics and PDE5I treatment data were obtained. Mean follow-up was 6.4 years (January 31, 2014) and all deaths were ascertained from GP records. Mean follow-up was 6.4 years (January 31, 2014) and all deaths were ascertained from GP records.

Findings: Of the 1,663 (23.7%) men prescribed a PDE5I, the proportion of deaths was significantly lower than those never prescribed (16.9% versus 29.4%). All-cause mortality rates (per 1000 person-years) were similarly lower (21.1 (9.1-24.5) versus 34.5 (32.5-36.5); P<0.001). There was a 38% reduction in all-cause mortality (univariate Cox proportional hazards HR: 0.62 (0.54-0.71); P<0.001) in men on a PDE5I over the period. This reduction remained but was attenuated (HR: 0.80 (0.65, 0.98); P<0.05) after multivariable regression adjusting for age (1.11 (1.09-1.12); P<0.001 per year), smoking history (1.31 (1.16-1.47); P<0.001), HbA1c, systolic BP, creatinine levels, prescribed statins, aspirin and beta-blocker use.

Interpretation: Around 70% of deaths in T2DM are attributable to cardiovascular disease. Our data demonstrates that PDE5I use is associated with significantly reduced mortality in men with T2DM at high risk of CVD. Further evidence is required to elucidate the role of PDE5Is in cardioprotection.
to monitor response to therapy as well as pharmacologic support of the circulation.

P7.3 IMPACT OF KIDNEY TRANSPLANTATION ON AORTIC STIFFNESS: RESULTS FROM 2-YEAR FOLLOW-UP

D. Turgeon a,b, C. Fortier a,b, S. Ignace c, S. De Serres a,b, I. Côté a,b, I. Houde a,b, M. Agharazia
1Universon Laval, Québec, Canada
2Chu de Québec Research Centre, Québec, Canada
3Chu de Nancy, Nancy, France

Objectives: Kidney transplantation (KTx) may improve arterial stiffness. The purpose of the present study is to examine the effects of KTx on aortic stiffness after 2 years of follow-up.

Method: In this prospective, longitudinal observational study, we studied hemodynamic parameters prior to KTx and 3, 6 and 24 months after a KTx in 59 dialysis patients. Aortic stiffness was measured by carotid-femoral pulse wave velocity (cf-PWV) and heart rate adjusted central augmentation index (AIx) was measured by arterial tonometry. A successful KTx was defined by an estimated eGFR of ≥45 mL/min/1.73m². Linear mixed model was used to take into account the repeated measures of aortic stiffness and mean blood pressure. Values are reported as mean±SEM

Results: The mean age was 48 years, with 70% male, 20% with cardiovascular disease and 25% diabetes. After adjusting for mean blood pressure, cf-PWV decreased significantly from 11.2±0.33 to 10.3±0.30 by 3 months (P = 0.042), but cf-PWV gradually increased to 10.8±0.31 and 11.2±0.33 (m/s) by 6 and 24 months and was not statistically different from the baseline. In an analysis stratified by age, the early improvement of aortic stiffness was only statistically significant for patients older than 50 years of age. However, MBP-adjusted AIx did not change significantly after KTx.

Conclusion: This study shows that there is an early reduction in aortic stiffness after KTx with a gradual return in aortic stiffness to baseline values after 2 years of follow-up. This study suggests a reduction in the rate of progression of aortic stiffness after KTx.

P7.4 AORTIC STIFFNESS IS ASSOCIATED WITH FUNCTIONAL LIMITATION (OR SIX MINUTE WALK DISTANCE) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THEERICA STUDY

M. Fisk a, D. Mohan a, C. Bolton a, J. Cockcroft b, W. MacNee b, C. McEnery c, R. Tal-Singer c, M. Polkey a, I. Wilkinson a
1University of Cambridge, Cambridge, UK
2Royal Brompton & Harefield Foundation NHS Trust, London, UK
3University of Nottingham, Nottingham, UK
4Wales Heart Institute, Cardiff University, Cardiff, UK
5University of Edinburgh, Edinburgh, UK
6GliaxosmithKline, PA, USA

Background: Six-minute walk distance (6MWD) independently predicts mortality and hospitalisation in Chronic Obstructive Pulmonary Disease (COPD) and is significantly reduced in COPD subjects with comorbidities of heart disease and hypertension. It also predicts cardiovascular events in stable coronary heart disease, and mortality in heart failure. We hypothesised that aortic stiffness is associated with 6MWD in COPD patients.

Methods: Interim analysis was performed on 354 stable subjects with COPD recruited to the ERICA (Evaluation of the role of inflammation in non-pulmonary manifestations of airways disease) study. Central haemodynamic measurements included aortic pulse wave velocity (aPWV) and augmentation index (AIx). Other measurements included carotid intima thickness, spiremometry, 6MWD, fibrinogen and high-sensitivity C reactive protein (hs-CRP).

Results: 210 out of 354 subjects (59%) were male, median (range) age 67 (43-84) years, 68% were former smokers. Mean apPWV was 10.2 (2.6) m/s. Linear regression analysis indicated a significant negative association between aPWV and 6MWD (p = 0.001). This relationship was maintained after adjustment for airflow limitation (Forced Expiratory Lung Volume in 1 second [FEV]), age, sex, MAP and supine HR, p = 0.011. A 1 ms increase in PWV was associated with a 9 m decrease in 6MWD (95% CI: 4-14 m, p = 0.001).

Conclusions: Aortic stiffness is associated with 6MWD in COPD, suggesting a link between vascular ageing and functional limitation in this patient group, which merits further investigation. Reduced 6MWD in COPD subjects with cardiovascular comorbidity, suggests aortic stiffness may be involved in the increased prevalence of cardiovascular events seen in COPD.

P7.5 PHENOTYPING OF ARTERIAL HYPERTENSION BY PULSE WAVE VELOCITY AND PLASMA RENIN ACTIVITY MEASUREMENT

E. Pavlova, Y. Kotsoskaya, Z. Kobalava
Peoples Friendship University of Russia, Moscow, Russia

Objective: To test K.Kario hypothesis (J Am S Hypertens 2010; 4(5):215-218) that predominant “arterial stiffness” (AS) and “volume-dependent” (V) types of arterial hypertension may exist and thus evaluation of arterial stiffness and volume-dependency status may help to identify between a calcium channel blocker (as “anti-stiffness” drug) and a diuretic (as “anti-volume” drug) to achieve blood pressure (BP) control.

Methods: Pulse wave velocity (PWV, SphygmoCor, AtCor, Australia) and plasma renin activity (PRA, radioimmuno assay) were measured in 124 (48 men) untreated hypertensive patients aged 50-65 years (mean 59.6±5.1 years) with GFR CKD-EPI >60 mL/min/1.73 mL. AS typing was done by individual PWV interpretation (Boutouyrie P., Vermeersch S.J. Eur Heart J 2010;31:2338-2350). PRA >0.65 ng/ml/h was considered as V-type, PRA >0.65 ng/ml/h - as renin (R) type.

Results: V-type was found in 57.3%, R-type in 42.7%, AS-type in 47.6% patients. Isolated (normal PWV) types were observed in 52.4%, isolated R-type was more prevalent (38.7%) than isolated V-type (13.7%). AS+V-type was found in 43.6%, AS+R-type - in 4.0%. It means that 76.1% of patients with V-type had elevated PWV and 91.5% of patients with increased AS are volume-dependent. Multifactor analysis failed to reveal independent predictors of isolated or mixed types, but independent correlation between PRA and PWV (p = -0.45, p = 0.001) and pulse pressure amplification (p = 0.76, p = 0.001) was found.

Conclusion: Significant overlap in “arterial stiffness” and “volume” types of arterial hypertension argues against possibility of differential choice between a calcium channel blocker and a diuretic for BP lowering guided by evaluation of PWV and PRA.